Currently T-DM1 is being tested in multiple clinical trials. Trastuzumab-DM1 (T-DM1, trastuzumab emtansine) is designed to combine the clinical benefits of trastuzumab with a potent microtubule-disrupting drug, DM1 (a maytansine derivative). T-DM1 is another HER2 directed antibody therapy recently approved for treatment of HER2-positive breast cancer. Trastuzumab (Herceptin®) is currently used as a treatment for patients whose breast tumors overexpress HER2/ErbB2. Notes: The current error page you are seeing can be replaced by a custom error page by modifying the "defaultRedirect" attribute of the application's configuration tag to point to a custom error page URL. Mechanism of action and preclinical data.
This tag should then have its "mode" attribute set to "Off". It could, however, be viewed by browsers running on the local server machine.ĭetails: To enable the details of this specific error message to be viewable on remote machines, please create a tag within a "web.config" configuration file located in the root directory of the current web application. This review summarises the clinical activity of T-DM1 in the treatment of HER2-positive breast cancer, outlines the multiple mechanisms of action of T-DM1 and describes various resistance. SD, standard deviation T-DM1, trastuzumab emtansine. from publication: Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives. DM1 concentrations were at least 50-fold lower (on a molar basis) than T-DM1 at all times (e.g., T-DM1 Cmax5.2M versus DM1 Cmax0.09M).
#T dm1 mechanism of action download#
The current custom error settings for this application prevent the details of the application error from being viewed remotely (for security reasons). Download scientific diagram Mechanism of action of Trastuzumab-Emtasine (T-DM1). Ado-trastuzumab emtansine (T-DM1) is a HER2-antibody-drug conjugate (ADC) that incorporates a HER2-targeted antibody (trastuzumab) with a microtubule inhibitor conjugate (maytansine or DM1) through a linker which is a nonreducible thioether bond. T-DM1 has been shown to retain the mechanism of action of trastuzumab as an antibody, including antibody-dependent cellular cytotoxicity (ADCC), inhibition. Runtime Error Description: An application error occurred on the server.
Runtime Error Server Error in '/' Application. TUKYSA (tucatinib) video resources, including an informational video on the mechanism of action for TUKYSA.